340B Drug Pricing Program
HRSA, which oversees the 340B program, has recognized the need for hospitals to partner with community and specialty pharmacies. Despite the demonstrated benefits to patients, these arrangements have been criticized by drug companies.
The AHA, 340B Health and the American Society of Health-System Pharmacists last week filed an amicus brief in a federal district court in Missouri, defending the state's law protecting 340B pricing for contract pharmacy arrangements.
The AHA, 340B Health and the American Society of Health-System Pharmacists last week filed an amicus brief in a federal district court in Missouri, defending the state's law protecting 340B pricing for contract pharmacy arrangements.
If Johnson & Johnson moves forward with its plan to undermine the 340B Drug Pricing Program by unilaterally imposing a rebate model rather than the longstanding upfront discount model, the Health Resources and Services Administration should take “immediate enforcement action,” including…
The American Hospital Association, 340B Health, and the American Society of Health-System Pharmacists (collectively, the “Proposed Amici”) respectfully move this Court for leave to file the attached amicus curiae brief in support of Defendants Attorney General Andrew Bailey, President of the…
If Johnson & Johnson moves forward with its plan to undermine the 340B Drug Pricing Program by unilaterally imposing a rebate model rather than the longstanding upfront discount model, the Health Resources and Services Administration should take “immediate enforcement action,” including…
If Johnson & Johnson moves forward with its plan to undermine the 340B Drug Pricing Program by unilaterally imposing a rebate model rather than the longstanding upfront discount model, the Health Resources and Services Administration should take “immediate enforcement action,” including…
AHA letter regarding the Health Resources and Services Administration’s response to Johnson & Johnson’s (J&J) most recent attempt to undermine the 340B Drug Pricing Program.
J&J announces major change to 340B pricing; HRSA responds to preemptive AHA advocacy.
Johnson & Johnson announced Aug. 23 that it would be fundamentally changing the way it makes 340B pricing available for two of its most popular products, Stelara and Xarelto.